John Trizzino, our President and Chief Operating Officer who will provide an update on our Sanofi partnership and finally Jim Kelly, Chief Financial Officer and Treasurer who will provide an ...

Novavax Inc (NASDAQ:NVAX) announced a wide-ranging partnership with Sanofi, which includes lead commercial responsibilities for the COVID-19 vaccine starting with the 2025-2026 vaccination season.

NVAX reports encouraging fourth-quarter results ... loss and said it expects its licensing deal with French drugmaker Sanofi for COVID-19 vaccines to generate royalties, and reduce selling ...

Despite potential opportunities, NVAX stock remains a “Sell” due ... royalties and other — primarily due to the deal with Sanofi. Total expenses were $931m, down from >$1.5bn in the prior ...

Novavax Inc (NASDAQ:NVAX) announced a wide-ranging partnership with Sanofi, which includes lead commercial responsibilities for the COVID-19 vaccine starting with the 2025-2026 vaccination season. The ...

Novavax (NVAX) stock jumped today following the release ... One thing that is worth noting is Novavax selling its Nuvaxovid COVID-19 vaccine to Sanofi (SNY). for the 2025 to 2026 flu season.

Several large investors have recently modified their holdings of NVAX. Sanofi purchased a new position in shares of Novavax in the fourth quarter worth about $55,319,000. Deep Track Capital LP ...

Sanofi Royalties Sanofi will initiate lead commercial ... Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most significant health challenges by leveraging its scientific expertise in ...

March 11, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that James ... to guide the Company through the partnership with Sanofi in 2024 and the subsequent transformative ...

NVAX reports encouraging fourth-quarter results ... Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi for COVID-19 vaccines ...

Novavax (NVAX) has recently seen a decrease in stock ... A significant part of this plan is a co-exclusive licensing agreement with Sanofi that could potentially bring in payments totaling up ...